15 results
8-K
EX-99.1
CTMX
CytomX Therapeutics Inc
8 Aug 23
CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
4:08pm
, and bispecific immunotherapies. As CMO, Dr. Chu will oversee clinical development of the Company’s diversified portfolio of Probody® therapeutic candidates
PRE 14A
1dwg787d
17 Apr 20
Preliminary proxy
4:30pm
8-K
owlhzp
21 Apr 16
CytomX and AbbVie Announce Strategic Collaboration for Probody Drug Conjugates
12:00am
- Prev
- 1
- Next